S100A4 and pachyonychia congenita: In addition, S100A4 knockdown increased the sensitivity of a PDAC cell line to gemcitabine (the first-line drug for advanced PC) treatment (53), thereby improving the therapeutic effect of the drug or the survival time of the patient.